迪哲医药：让创新真正触达患者

Core Insights - Dize Pharmaceutical was listed on the Sci-Tech Innovation Board in December 2021, which significantly accelerated the company's progress in technological self-reliance [1] - The company emphasizes that technological innovation stems from keen insights into unmet clinical needs and relies on sustained R&D investment [1] - Dize Pharmaceutical has successfully commercialized two innovative drugs, which have entered medical insurance and achieved market expansion, demonstrating the conversion of R&D results into market value [1] Company Strategy - The company maintains a strategic focus and does not reduce R&D investment for short-term profit goals [1] - Dize Pharmaceutical completed a refinancing as the first unprofitable company under the "Eight Articles of Sci-Tech Innovation Board," providing solid support for future development [1] - The company believes that support from the capital market is crucial for innovative enterprises to transform technological achievements into social value and provide long-term returns to investors [1] Global Competitiveness - Dize Pharmaceutical aims to serve domestic patients while also possessing global competitiveness through overseas applications and international clinical research [2] - The approval of the drug Shuwozhe in both China and the United States reflects the international competitiveness of the company's R&D achievements [2] - The company emphasizes long-termism, value orientation, and a sense of responsibility in decision-making, aiming to contribute to high-quality development in the capital market [2] Future Outlook - Dize Pharmaceutical will continue to adhere to an innovation-driven and high-quality development strategy, optimize corporate governance, and enhance investment value [2] - The company aims to create value for patients and society through its practices and contribute to innovation [2]